The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGamma Communications Regulatory News (GAMA)

Share Price Information for Gamma Communications (GAMA)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,322.00
Bid: 1,316.00
Ask: 1,320.00
Change: 2.00 (0.15%)
Spread: 4.00 (0.304%)
Open: 1,318.00
High: 1,332.00
Low: 1,314.00
Prev. Close: 1,322.00
GAMA Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Trading Statement

12 Jan 2022 07:00

RNS Number : 1299Y
Gamma Communications PLC
12 January 2022
 

12 January 2022

Gamma Communications plc

Trading Update

 

Full year adj EBITDA and adj EPS anticipated to be in the top half of the range of market expectations

 

Gamma Communications plc ("Gamma"), a leading provider of Unified Communication as a Service ("UCaaS") products, announces a trading update for the year ended 31 December 2021.

 

Trading

There is a continued strong demand in the UK and European business markets for Gamma's portfolio of UCaaS products, which through both Direct and Indirect channels have performed well throughout the trading period.

 

Market expectations were raised following the announcement of Gamma's trading updates issued on 20 May and 13 July 2021. The Board expects that revenue for the year ended 31 December 2021 will be within the range of current market expectations and adjusted EBITDA and adjusted EPS will be in the upper half of current market expectations*. 

 

Cash

The closing net cash balance was £49.5m (2020: £48.0m) which was ahead of expectations due to a strong working capital performance. The year on year net cash increase is particularly pleasing given that during 2021 Gamma spent £49.3m on acquisitions (primarily the acquisition of Mission Labs), increased investment in product development compared to 2020 and paid dividends to shareholders totalling £11.7m (2020:£10.4m), a year on year increase of 12.5%.

 

Overview of the year

 

Some of the highlights from the year include:

 

· The group performed strongly throughout 2021 despite the ongoing economic uncertainty caused by Covid-19. Gamma's recurring revenue model has proved robust, and importantly, its product set supports businesses which have a need to both operate and work remotely.

· Unit sales of our core UCaaS products have continued to be strong in both the UK and Europe.

· In our Direct business we have won several new multi-year contracts, including The Berkeley Group (Horizon Contact), NFU Mutual (SDWAN) and also a large central Government department (fully managed Microsoft Teams deployment).

· In March, Gamma acquired Mission Labs bringing additional technology and product capabilities to the Group (Smart Agent and Circle Loop) as well as adding important software development capabilities. The integration of Mission Labs has gone well and is proceeding in line with expectations. Gamma is leveraging Mission Labs' relationship with Amazon to expand its offering into the Enterprise market through the Smart Agent product, which has generated new customers during the period. The Circle Loop product (which is a digitally based Cloud PBX product aimed at the micro business market) is also growing in line with expectations. Moreover, the Mission Labs team is working well with the existing Gamma technology and product teams which have collectively accelerated progress on product and feature development.

· The Group has continued to develop its suite of products and has launched Horizon Contact (which is a Contact Centre as a Service product) and has integrated Microsoft Teams to its market leading Horizon Cloud PBX product.

· Gamma has continued to develop its relationship with Microsoft and launched Microsoft Teams Direct Routing in March - essentially a SIP Trunk which works specifically with Teams. Gamma was also added to Microsoft's select list of carriers who offer the "Operator Connect" service which is designed to enable seamless and integrated calling between Teams and the local telephony infrastructure (known as the PSTN). This selection demonstrates the strength of Gamma having both a UCaaS offering as well as an ability to provide integration to the PSTN.

 

The Board expects to announce results for the year ended 31 December 2021 on Tuesday 22 March.

 

*Company compiled market expectations for the full year ended 31 December 2021 are revenue (£444.5m-£455.6m), adjusted EBITDA (£90.5m-£96.0m) and adjusted EPS (57.6p-64.0p).

 

 

Andrew Taylor, Chief Executive, commented:

"We are pleased that Gamma has grown very strongly throughout 2021 while continuing to invest significantly in our business and executing against all aspects of our strategic plan. The demand for cloud communications across all geographies and market segments is positive and the long-term growth opportunity for Gamma is very significant.

 

"Our UCaaS product strategy is progressing very well, and we are pleased with the overall performance of our product set, in particular the new products which we launched through the year. Our product set, digital channel and software development capabilities have been strengthened with the acquisition of Mission Labs and we are very pleased with how this is performing.

 

"I would like to take this opportunity to personally thank our staff and partners for all of their support and hard work throughout the year."

 

END

 

Gamma Communications plc

Andrew Taylor, Chief Executive Officer

Andrew Belshaw, Chief Financial Officer

Tel: +44 (0) 333 006 5972

 

 

Tulchan Communications LLP

James Macey White / Matt Low

Tel: +44 (0) 207 353 4200

 

 

Investec Bank plc (NOMAD & Broker)

Tel: +44 (0) 207 597 5970

Patrick Robb / Virginia Bull

 

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
TSTKZGMMNMDGZZM
Date   Source Headline
24th Apr 20247:00 amRNSTransaction in Own Shares
23rd Apr 20247:00 amRNSTransaction in Own Shares
22nd Apr 20247:00 amRNSTransaction in Own Shares
19th Apr 20247:00 amRNSTransaction in Own Shares
18th Apr 20247:00 amRNSTransaction in Own Shares
17th Apr 20247:00 amRNSTransaction in Own Shares
16th Apr 202411:09 amRNSHolding(s) in Company
16th Apr 20247:00 amRNSTransaction in Own Shares
15th Apr 20241:57 pmRNSDirector/PDMR Shareholding
15th Apr 20247:00 amRNSTransaction in Own Shares
12th Apr 20243:19 pmRNSPublication of Notice of AGM
12th Apr 20243:05 pmRNSDirector/PDMR Shareholding
12th Apr 20243:00 pmRNSDirector/PDMR Shareholding
12th Apr 20247:00 amRNSTransaction in Own Shares
11th Apr 20247:00 amRNSTransaction in Own Shares
10th Apr 20247:00 amRNSTransaction in Own Shares
9th Apr 20247:00 amRNSTransaction in Own Shares
8th Apr 20247:00 amRNSTransaction in Own Shares
5th Apr 20247:00 amRNSTransaction in Own Shares
4th Apr 20247:00 amRNSTransaction in Own Shares
3rd Apr 20249:36 amRNSTransaction in Own Shares
3rd Apr 20247:55 amRNSTransaction in Own Shares
2nd Apr 20246:00 pmRNSTotal Voting Rights
2nd Apr 20247:00 amRNSTransaction in Own Shares
28th Mar 20247:00 amRNSTransaction in Own Shares
27th Mar 20247:00 amRNSTransaction in Own Shares
26th Mar 20247:00 amRNSTransaction in Own Shares
25th Mar 20247:02 amRNSShare buyback programme
25th Mar 20247:01 amRNSFinal Results
25th Mar 20247:00 amRNSBoard Change and Committee Composition
22nd Mar 20245:20 pmRNSHolding(s) in Company
14th Mar 20247:30 amRNSDirector/PDMR Shareholding
1st Mar 20242:31 pmRNSTotal Voting Rights
14th Feb 20248:38 amRNSDirector/PDMR Shareholding
13th Feb 20248:00 amRNSSite visit for investors
1st Feb 20241:49 pmRNSTotal Voting Rights
17th Jan 20243:51 pmRNSHolding(s) in Company
16th Jan 20247:00 amRNSScheduled Trading Update
15th Jan 20244:46 pmRNSDirector/PDMR Shareholding
2nd Jan 202410:24 amRNSTotal Voting Rights
28th Dec 20234:10 pmRNSHolding(s) in Company
21st Dec 20235:34 pmRNSHolding(s) in Company
21st Dec 20235:33 pmRNSHolding(s) in Company
13th Dec 20235:35 pmRNSDirector/PDMR Shareholding
13th Dec 202312:34 pmRNSIssue of Equity
5th Dec 20237:00 amRNSTotal Voting Rights
30th Nov 20234:13 pmRNSHolding(s) in Company
15th Nov 202310:31 amRNSDirector/PDMR Shareholding
9th Nov 20237:00 amRNSBlock listing Interim Review
1st Nov 202311:13 amRNSTotal Voting Rights

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.